| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| NANOMIX Corp | Interim CFO, Director | Common Stock | 1,695,176 | $423,794 | $0.2500 | 30 Nov 2022 | Direct |
| NANOMIX Corp | Interim CFO, Director | Incentive Stock Option (right to buy) | 1,695,176 | 30 Nov 2022 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| /report/000121390022080579-ludvigson-david-2022-12-01 | NANOMIX Corp | 01 Dec 2022 | 2 | +$2,447 | 4 | Interim CFO, Director | 16 Dec 2022, 16:12 |
| /report/000121390021034842-ludvigson-david-2021-06-04 | Boston Therapeutics, Inc. | 04 Jun 2021 | 0 | $0 | 3 | CEO and President, Director | 29 Jun 2021, 20:46 |